RE: DYOR11 Jun 2020 09:41
wording by finncap makes it clear
Open Orphan*
Major contract signed with leading pharma company
Open Orphan has announced a major contract with one of the top four pharmaceutical companies in the world. The contract is with ORPH’s subsidiary, Venn Life Sciences, and builds on earlier successful contracts between Venn and the leading vaccine developer. Venn will obtain and support market access of a newly developed, non-COVID-19, vaccine to the EU and US market until the end of 2020. ORPH also launched its COVID-19 antibody testing service last week, targeting large employer groups, and is also developing a COVID-19 challenge model, both of which could be transformational for the business. We leave forecasts unchanged but with room for upside depending on uptake of the test, and reiterate our target price of 19p.